Becton, Dickinson and Company BDX
At closeNov 5, 2026, 4:15 AM EST
Pre-market · Nov 5, 4:15 AM ET
- YTD
- +37.11%
- 1 year
- +50.85%
- Market cap
- 56.98B
- Revenue (ttm)
- 22.48B
- Profit margin
- 4.19%
- EPS (ttm)
- 4.30
- Shares out
- 272.39M
- P/E ratio
- 48.65
- Forward P/E
- 15.73
- Dividend
- 4.20 (2.12%)
- Ex-dividend date
- Sep 8, 2026
- YTD return
- +37.11%
- 1-year return
- +50.85%
- Volume
- 4.46M
- Avg volume
- 1.74M
- Open
- 203.00
- Previous close
- 198.17
- Day's range
- 200.30 – 209.84
- 52-week range
- 127.59 – 209.84
- Beta
- 0.28
- Analysts
- Buy
- Price target
- 195.57 (-6.5%)
- Earnings date
- Nov 5, 2026
2Y +22.63 (+12.13%)
Key statistics
- Enterprise value
- 70.08B
- PEG ratio
- 1.11
- Price / sales
- 2.53
- Price / book
- 2.33
- Dividend yield
- 2.12%
- Payout ratio
- 72.49%
- Revenue growth
- 5.40%
- Free cash flow
- 4.48B
- Total cash
- 709.00M
- Total debt
- 16.81B
- Return on equity
- 6.61%
- Short % of float
- 3.73%
- 50-day average
- 186.88
- 200-day average
- 166.33
Analyst view
Consensus: buy
- Target (low)
- 165.00
- Target (mean)
- 195.57
- Target (high)
- 225.00
- Strong buy1
- Buy7
- Hold7
- Sell0
- Strong sell1
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 4.07.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 4.07 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 3.14 | 3.23 | +0.09 | +2.87% |
| May 7, 2026 | Mar 31, 2026 | 2.78 | 2.90 | +0.12 | +4.32% |
| Feb 9, 2026 | Dec 31, 2025 | 2.21 | 2.91 | +0.70 | +31.67% |
| Nov 6, 2025 | Sep 30, 2025 | 3.92 | 3.96 | +0.04 | +1.02% |
| Aug 7, 2025 | Jun 30, 2025 | 3.40 | 3.68 | +0.28 | +8.24% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | Barclays | init | — | Underweight |
| Aug 31, 2026 | B of A Securities | main | Neutral | Neutral |
| Aug 13, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Aug 7, 2026 | Citigroup | main | Buy | Buy |
| Aug 7, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Aug 7, 2026 | Piper Sandler | main | Neutral | Neutral |
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- bd.com
News
Toyota, ConocoPhillips On Deck Thursday As Auto Demand, Oil Prices Face Test 
BD Names Bridget Bagnato Worldwide President of Peripheral Intervention 
BDX Gears Up to Report Q4 Results: How to Play the Stock? 
Becton Dickinson (BDX) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates 
BD Launches Liverty TIPS Stent Graft to Expand U.S. Treatment 
Emerson Among 14 Dividend Growth Companies To Announce Annual Dividend Increases In First Half Of November 
Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy? 
American Century Equity Income Fund Q3 2026 Portfolio Activity 
Barclays Initiates Coverage On Becton Dickinson with Underweight Rating, Announces Price Target of $165 
Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing
Your note
Sign in to keep a note on BDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DELOREFICE CHRISTOPHER | Chief Financial Officer | Stock Award(Grant) | Nov 25, 2025 | 22,982 |
| FELD MICHAEL | Officer | Sale | Oct 25, 2026 | 19,568 |
| FRASER CLAIRE | Director | Sale | Sep 9, 2025 | 22,226 |
| GOETTE ROLAND | Officer | Sale | Aug 10, 2026 | 16,635 |
| JONES CHRISTOPHER IAN MONTAGUE | Director | Stock Award(Grant) | Jan 26, 2026 | 24,304 |
| MUHSIN BILAL | Officer | Stock Award(Grant) | Jun 30, 2026 | 41,359 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.93% | 24,592,166 | 5.14B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 17,987,834 | 3.76B | Jun 29, 2026 |
| State Street Corporation | 5.44% | 15,000,064 | 3.14B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.43% | 14,974,136 | 3.13B | Jun 29, 2026 |
| First Eagle Investment Management, LLC | 5.01% | 13,815,335 | 2.89B | Jun 29, 2026 |
| Invesco Ltd. | 3.23% | 8,898,488 | 1.86B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| First Eagle Funds-First Eagle Global Fund | 3.32% | 9,151,995 | 1.91B | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 8,747,261 | 1.83B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 7,136,026 | 1.49B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.17% | 5,970,167 | 1.25B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.32% | 3,629,584 | 759.24M | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.28% | 3,539,936 | 740.48M | Sep 29, 2026 |